An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 324 participants.
Also called NCT01103960
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 324 participants
- Sponsor
- Registry
-
NCT01103960
-
- Other papers using this trial's data
- A randomized, double-blind study to evaluate the efficacy and safety of a single-pill combination of telmisartan 80 mg/amlodipine 5 mg versus amlodipine 5 mg in hypertensive Asian patients
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- Not reported
- Results first posted
- Countries
- China, Malaysia, Philippines
- Registry status
- Completed
Technical summary
Registry record NCT01103960. Randomized; double masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2011-08 (actual). Results posted on 2012-09-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- An Eight-week Randomized,Double-blind Study to Evaluate the Efficacy and Safety of Fixed-dose Combinations of T80+A5 Versus A5 Monotherapy in Patients With Hypertension Who Fail to Respond Adequately to Treatment With A5 Monotherapy
- Condition
- Hypertension
- Intervention (Drug)
- Telmisartan80mg+Amlodipine5mg
- Intervention (Drug)
- amlodipine 5mg
- Intervention (Drug)
- Telmisartan80mg+Amlodipine 5mg
- Lead sponsor
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct01103960- Content hash
71d052d8b3e4223d510bcbba26a10b3b0636ed2b9c3851ffdbdba2996dbd8c63